Detailed disclosure is attached.

21 August 2026 BSE Limited (Security Code: 524314) Phiroze Jeejeeboy Towers, Dalal Street, Fort, Mumbai- 400 001. Dear Sirs, Sub: Re-appointment of Mr. Aalap Prajapati, Managing Director & Chief Executive Officer of the Company – Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations) Pursuant to Regulation 30(6) read with Schedule III and other applicable SEBI Listing Regulations, we hereby inform you that the members of the Company at the 41st Annual General Meeting held today i.e. Friday, 21 August 2026, have inter alia approved the re-appointment of Mr. Aalap Prajapati (DIN:08088327) as the Managing Director, designated as “Managing Director & CEO” of the Company for three consecutive years commencing from 28 October 2026 to 27 October 2029 (both days inclusive). Details with respect to the re-appointment of Mr. Aalap Prajapati as the Managing Director & CEO of the Company, as required under Regulation 30(6) read with Para A (7) of Part A of Schedule III of the SEBI Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated 30 January 2026 including amendments thereon, are provided in Annexure I to this letter. This intimation is also being uploaded on the website of the Company at https://www.gujaratterce.in/announcements/. Thanking you For Gujarat Terce Laboratories Limited Ashka Solanki Company Secretary ANNEXURE I Details with respect to re-appointment of Mr. Aalap Prajapati as the Managing Director & CEO of the Company under Regulation 30(6) read with Para A(7) of Part A of Schedule III of the Listing Regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13 July 2023 Sr.No. Details of events that needs to be provided Information of such event(s) 1. Reason for change viz. appointment, re- The Members of the Company at the 41st Annual General appointment, resignation, removal, death or Meeting of the Company held today i.e. Friday, 21 August otherwise 2026 have interalia approved the re-appointment of Mr. Aalap Prajapati (DIN: 08088327), as the Managing Director & CEO of the Company, liable to retire by rotation, for a period of 3 (three) years with effect from 28 October 2026 to 27 October 2029 (both days inclusive). 2. Date of appointment/re-appointment/ Date of Re-appointment- 28 October 2026 cessation (as applicable) and term of appointment/re-appointment Tenure of re-appointment- 3 years commencing from 28 October 2026 to 27 October 2029 (both days inclusive) 3. Brief Profile (in case of appointment) Mr. Aalap Prajapati has over 15 years of experience in the pharmaceutical sector. He possesses experience in the pharmaceutical and healthcare industry with expertise in business strategy, operations management, marketing and business development. He has been actively associated with the Company’s leadership and growth initiatives and plays a key role in driving operational efficiency and long-term business development of the Company. He holds a management qualification from B.K. School of Business Management with specialization in Marketing and Operations. 4. Disclosure of relationships between He is the Son of Mr. Natwarbhai Prajapati who is the Whole- directors (in case of appointment of a Time Director of the Company. director) 5. Information as required pursuant to BSE Mr. Aalap Prajapati is not debarred from holding the office of Circular with ref. no. LIST/COMP/14/201819 director by virtue of any SEBI order or any other such authority and the National Stock Exchange of India Limited Circular with ref. no. NSE/CML/2018/ 24, both dated 20 June 2018 ************************